- Home
- TSVT vs AOMR Comparison
TSVT vs AOMR Comparison
Compare TSVT & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- AOMR
- Stock Information
- Founded
- TSVT 2021
- AOMR 2018
- Country
- TSVT United States
- AOMR United States
- Employees
- TSVT N/A
- AOMR N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- AOMR Real Estate Investment Trusts
- Sector
- TSVT Health Care
- AOMR Real Estate
- Exchange
- TSVT Nasdaq
- AOMR Nasdaq
- Market Cap
- TSVT 253.9M
- AOMR 240.9M
- IPO Year
- TSVT N/A
- AOMR 2021
- Fundamental
- Price
- TSVT $5.00
- AOMR $9.87
- Analyst Decision
- TSVT Buy
- AOMR Buy
- Analyst Count
- TSVT 6
- AOMR 6
- Target Price
- TSVT $10.40
- AOMR $11.70
- AVG Volume (30 Days)
- TSVT 340.7K
- AOMR 143.1K
- Earning Date
- TSVT 11-12-2024
- AOMR 11-05-2024
- Dividend Yield
- TSVT N/A
- AOMR 12.96%
- EPS Growth
- TSVT N/A
- AOMR N/A
- EPS
- TSVT N/A
- AOMR 1.97
- Revenue
- TSVT $44,120,000.00
- AOMR $69,248,000.00
- Revenue This Year
- TSVT N/A
- AOMR N/A
- Revenue Next Year
- TSVT $22.42
- AOMR $30.57
- P/E Ratio
- TSVT N/A
- AOMR $5.03
- Revenue Growth
- TSVT N/A
- AOMR N/A
- 52 Week Low
- TSVT $1.54
- AOMR $7.85
- 52 Week High
- TSVT $6.40
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- TSVT 57.40
- AOMR 29.17
- Support Level
- TSVT $4.60
- AOMR $9.80
- Resistance Level
- TSVT $4.90
- AOMR $9.98
- Average True Range (ATR)
- TSVT 0.29
- AOMR 0.17
- MACD
- TSVT 0.02
- AOMR 0.00
- Stochastic Oscillator
- TSVT 88.76
- AOMR 10.45
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.